Utilizing Endoscopic Ultrasound-Guided Fine Needle Aspiration in Identifying Molecular Targets for Pancreatic Cancer
Pancreatic cancer remains a devastating disease, with poor survival rates and high recurrence rates with current treatment regimens. Over the years we have come to understand the complex biology of this cancer, involving cross-talking signaling pathways that proffers resistance to current therapy. Several molecularly targeted agents remain in development. At the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, an abstract (#4051) was presented which explored using endoscopic ultrasound-guided fine needle aspiration of pancreatic cancer tissue to identify molecular targets, and argued for the feasibility of personalizing pancreatic cancer therapy based on the activated molecular pathways identified. We summarize their findings and discuss the possibility of utilizing this model to obtain a better understanding of pancreatic cancer at each stage of its metamorphosis and target therapy at these different levels.
Image: Jaharis Family Center for Biomedical and Nutrition Sciences. Tufts University School of Medicine. Boston, MA, USA.
National Cancer Institute. SEER Stat Fact Sheets: Pancreas. http://seer.cancer.gov/statfacts/html/ 2013
Richter J, Saif MW. Updates in adjuvant therapy in pancreatic cancer: gemcitabine and beyond. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium." Orlando, FL, USA. January 22-24, 2010. JOP. 2010 Mar 5;11(2):144-7.
Vaccaro V, Gelibter A, Bria E, Iapicca P, Cappello P, Di Modugno F, Pino MS, Nuzzo C, Cognetti F, Novelli F, Nistico P, Milella M. Molecular and genetic bases of pancreatic cancer. Curr Drug Targets. 2012 Jun;13(6):731-43.
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20;25(15):1960-6.
Strimpakos A, Saif MW, Syrigos KN. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev. 2008 Sep;27(3):495-522
Huang ZQ, Saluja AK, Dudeja V, Vickers SM, Buchsbaum DJ. Molecular targeted approaches for treatment of pancreatic cancer. Curr Pharm Des. 2011;17(21):2221-38.
Wang-Gillam A, Wani S, Langley EL, et al. Identifying targetable pathways in pancreatic cancer from endoscopic ultrasound-guided fine needle aspirates (EUS-FNA): Providing a personalized approach to targeted therapy. 2013 American Society of Clinical Oncology Annual Meeting. Abstract #4051
Troiani T, Martinelli E, Capasso A, Morgillo F, Orditura M, De Vita F, Ciardiello F. Targeting EGFR in pancreatic cancer treatment. Curr Drug Targets. 2012 Jun;13(6):802-10
Copyright (c) 2014 Onyekachi Henry Ogbonna, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.